Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new antihyperglycemic medications approved for treatment of type 2 diabetes. Adding a SGLT-2 inhibitors to other antihyperglycemic medications was shown to reduce glucose toxicity, improve insulin sensitivity and reduce body weight. Consequently, daily insulin dose may be reduced without compromising glycemic control.